(Generalised epilepsy and complex partial epilepsy)

N03A Adjunctive therapy in the partial onset seizures in epilepsy

Risk benefit in children The risk benefit profile of vigabatrin monotherapy in children with partial epilepsy is negative.

There will be some type of serious complications such as mental retardation, cerebral palsy, deafness, epilepsy or partial blindness.

LYRICA is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults.

Epilepsy Epilepsy typically requires long term therapy.

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

Epilepsy

In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

Long term follow up studies of children with therapy resistant epilepsy have generally demonstrated adequate control of partial epilepsies with or without secondary generalization.

treatment in adult and children patients with therapy resistant partial epilepsy with or without secondary generalization and as monotherapy in children with infantile spasms

Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy

8 Epilepsy

Vimpat is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

Vimpat is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

In children with therapy resistant partial epilepsy, greater than 50 reduction in seizure frequency has been observed in 40 60 of patients during add on vigabatrin treatment.

loss of consciousness, epilepsy, petit mal epilepsy, convulsion, facial palsy, polyneuropathy, areflexia

phenytoin (for epilepsy)

Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Zonegran is used as an add on to existing epilepsy treatment in adult patients who have partial seizures (epileptic fits starting in one specific part of the brain).

Keppra can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial onset seizures (fits) with or without secondary generalisation.

if you have epilepsy.

Precautions relating to epilepsy

juvenile myoclonic epilepsy, and primary generalised tonic clonic seizures in patients with idiopathic generalised epilepsy.

Epilepsy As with other antidepressants, paroxetine should be used with caution in patients with epilepsy.

The therapeutic indication of gabapentin as adjunctive epilepsy therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above is well established.

Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.